All In Biotech

Drug Trial Radar · NCT07479485

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Apr 2028

Study completion Apr 2029

Sponsor

Lead sponsor
Lepu Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma

Interventions

  • MRG006ADrug

    Administrated intravenously

  • PucotenlimabDrug

    Administrated intravenously

  • BevacizumabDrug

    Administrated intravenously

  • PD1/VEGF antibodyDrug

    Administrated intravenously

  • TKIDrug

    Administrated intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Up to 2 years
  2. Recommended Phase 2 DoseTime frame: 1 year

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing You An Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences.

    Beijing, Beijing Municipality, China · Recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • The First Affiliated Hospital With Nanjing Medical University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

  • Lishui Central Hospital

    Lishui, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.